Im­muneer­ing cuts neu­ro­science pro­grams to fo­cus on on­col­o­gy, ex­tend cash run­way

Im­muneer­ing has sus­pend­ed its dis­cov­ery-stage neu­ro­science pro­gram and is now fo­cus­ing ex­clu­sive­ly on its on­col­o­gy pipeline in or­der to ex­tend its cash run­way in­to 2024, the com­pa­ny an­nounced in its Q4 re­lease.

The com­pa­ny’s lead pro­gram, IMM-1-104, is cur­rent­ly in a US-based Phase I/IIa study in pa­tients with ad­vanced sol­id tu­mors with RAS mu­ta­tions. In Sep­tem­ber last year, the can­di­date re­ceived IND clear­ance as an oral, once-dai­ly monother­a­py. Im­muneer­ing hopes to ex­tend it to oth­er can­cers, in­clud­ing mu­tat­ed pan­cre­at­ic, melanoma, lung and col­orec­tal can­cers, based on Phase I re­sults.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.